Lenalidomide in follicular lymphoma.

Abstract

Lenalidomide is an immunomodulatory drug approved in the United States for use with rituximab in patients with relapsed/refractory follicular lymphoma. We reviewed data from trials addressing the safety and efficacy of lenalidomide alone and in combination with rituximab as a first-line therapy and as a treatment of patients with relapsed/refractory follicular lymphoma. Lenalidomide-rituximab has been demonstrated to be an effective chemotherapy-free therapy that improves upon single-agent rituximab and may become an alternative to chemoimmunotherapy.

• Authors: Christopher R Flowers, John P Leonard, Nathan H Fowler
• Journal: Blood (Blood) Vol. 135 Issue 24 Pg. 2133-2136 (06 11 2020) ISSN: 1528-0020 [Electronic] United States
• PMID: 32236519 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Review)
• Copyright: © 2020 by The American Society of Hematology.

Chemical References

• Antineoplastic Agents, Immunological
• Immunologic Factors
• Rituximab
• Lenalidomide

Topics

• Antineoplastic Agents, Immunological (administration & dosage)
• Antineoplastic Combined Chemotherapy Protocols
• Clinical Trials as Topic
• Humans
• Immunologic Factors (administration & dosage, therapeutic use)
• Lenalidomide (administration & dosage, therapeutic use)
• Lymphoma, Follicular (drug therapy)
• Rituximab (administration & dosage)